Frank Hamo, PhD in biomedical engineering, is the founder and CEO of MTI. He spent his entire biomedical engineering career bridging the gap between medicine and engineering to deliver advanced healthcare monitoring options. His mission is to utilize latest biomedical engineering technology to improve early detection, monitoring, and screening devices, improve operational
efficiency of healthcare organizations to save billions of dollars in medical
treatment, replace current medical screening methods, and actualize portable at- home devices.
He had lost seven members of his family for cancer therefore he spent numbers of years looking at cancer research because he believes understanding the disease and how to approach and manage it on time can increase the chances of survivor and recovery; he comes to the conclusion that early prediction, early signs and detection of cancer can Concore it at early stages before losing control, the same time he believes cancer cells can be defeated by under- standing how the immune system attacks foreign antigen.
Also, for the last two years, since COVID-19 emerged as a global pandemic, Hamo has been tracking the virus mutation from day one and providing recommendations for diagnosis, symptoms management to assist physicians and health workers in distinguishing between COVID-19 related illness,

Through many years of gained experience in cells biology I believe quantum biology can improve disease screening and targeted treatment at cellular level.